<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The biological agents approved for the treatment of patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> - bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor A, along with cetuximab and panitumumab, two monoclonal antibodies that target the epidermal growth factor receptor - are associated with a number of adverse events that range in severity from relatively mild to potentially life threatening </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000822'>Hypertension</z:hpo>, <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo>, <z:hpo ids='HP_0000093'>proteinuria</z:hpo>, <z:mp ids='MP_0001914'>bleeding</z:mp>, and gastrointestinal <z:mpath ids='MPATH_81'>perforation</z:mpath> have <z:hpo ids='HP_0000001'>all</z:hpo> been associated with bevacizumab, while dermatologic toxicities are common with cetuximab and panitumumab </plain></SENT>
<SENT sid="2" pm="."><plain>Hypersensitivity reactions and <z:hpo ids='HP_0002917'>hypomagnesemia</z:hpo> are also a concern with cetuximab and panitumumab </plain></SENT>
<SENT sid="3" pm="."><plain>The frequency of these adverse events in randomized clinical trials is reviewed, and recommendations for managing these events in patients undergoing treatment for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> are provided </plain></SENT>
</text></document>